Vascular endothelial growth factor gene polymorphisms and vitreous proteome changes in diabetic retinopathy

Seminars in Ophthalmology

Volumn 28, Issue 5-6, 2013, Pages 347-354

  Dyer, Kelli H ^a   Silva, Paolo S ^a,b   Sun, Jennifer K ^a,b  

^a JOSLIN DIABETES CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

C 634G polymorphism; Carbonic anhydrase I (CA I); Kallikrein kinin system; Rs3025021 polymorphism; Rs699947 polymorphism; Single nucleotide polymorphisms (SNPs)

Indexed keywords

CARBONATE DEHYDRATASE; KALLIKREIN; KININ; PROTEOME;

ARTICLE; BLOOD VESSEL PERMEABILITY; DIABETIC RETINOPATHY; DNA POLYMORPHISM; GENE; GENE EXPRESSION; GENETIC PREDISPOSITION; HUMAN; PRIORITY JOURNAL; RETINA MACULA EDEMA; SINGLE NUCLEOTIDE POLYMORPHISM; VASCULAR ENDOTHELIAL GROWTH FACTOR GENE; VITREOUS BODY;

CARBONIC ANHYDRASE I; DIABETIC RETINOPATHY; EYE PROTEINS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KALLIKREIN-KININ SYSTEM; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 84886426676     PISSN: 08820538     EISSN: 17445205     Source Type: Journal    
DOI: 10.3109/08820538.2013.825284     Document Type: Article

References (46)

1. Al-Latayfeh M. Antiangiogenic therapy for ischemic retinopathies. Cold Spring Harbor Perspectives in Medicine. 2012;2:a006411.
2. Ferrara N. Vascular endothelial growth factor. European Journal of Cancer. 1996; 32A:2413-2422.
3. Mbanya JC. Global Diabetes Plan 2011-2021, Brussels, Belgium: International Diabetes Federation, 2011.
4. Nathan DM. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: The Diabetes Control and Complications Trial. Arch Ophthalmol. 2008;126(12):1707- 1715.
5. Abhary S, Burdon KB. Common sequence variation in the VEGFA gene predicts risk of diabetic retinopathy. Investigative Ophthalmology and Visual Science. 2009;50: 5552-5558.
6. Al-Kateb H, Mirea L. Multiple variants in vascular endo-thelial growth factor (VEGFA) are risk factors for time to severe retinopathy in type 1 diabetes: The DCCT/EDIC Genetics Study. Diabetes. 2007;56:2161-2168.
7. Aiello LP, Ferrara N, King GL. Hypoxic regulation and bioactivity of vascular endothelial growth factor: Characterization in retinal microvascular pericytes and pigment epithelial cells. Invest Ophthalmol Vis Sci. 1994;35: 1868-1868.
8. Lu M, Adamis AP. Vascular endothelial growth factor gene regulation and action in diabetic retiopathy. Ophthalmol Clin N Am. 2002;15:69-79.
9. Senger DR. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res. 1986;46:5629-5632.
10. Aiello LP, Avery RL, Arrigg PG. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. The New England Journal of Medicine. 1994;331:1480-1487.
11. Tolentina MJ. Intravitreal injections of vascular endothe-lial growth factor produce retinal ischemia and micro-angiopathy in an adult primate. Ophthalmol 1996;103: 1820-1828.
12. Tolentina MJ. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a non-human primate. Arch Ophthalmol. 1996; 114:964-970.
13. Adamis AP, Miller JW. Vascular permeability factor (vascular endothelial growth factor) is produced in the retina and elevated levels are present in the aqueous humor of eyes with iris neovascularization. Invest Ophthalmol Vis Sci. 1993;34:1440-1440.
14. Adamis AP, Miller JW. Increased vascular endothelial growth factor levels in the vitreous of eyes with prolifera-tive diabetic retinopathy. Am J Ophthalmol. 1994; 118(4):445-450.
15. Aiello LP, Pierce EA. Suppression of retinal neovascular-ization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Pro Natl Acad Sci USA. 1995;92:10457-10461.
16. Robinson GS, Pierce EA. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of prolifera-tive retinopathy. Proc Natl Acad Sci USA. 1996; 93(10):4851-4856.
17. Miller JW, Adamis AP. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol. 1994;145(3):574-584
18. The Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010; 117(6):1064-1077.
19. Nguyen QD, Brown DM. Ranibizumab for diabetic macu-lar edema: Results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789-801.
20. Bandello, MP. The RESTORE study: Ranibizumab mono-therapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011; 118(4):615-625.
21. Kaines, MM. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: Report 2. Ophthalmology. 2010;117(6):1078-1086.
22. Avery RL, Pearlman J. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113(10):1695.e1-15.
23. Ford KM, D'Amore PA. Molecular regulation of vascular endothelial growth factor expression in the retinal pigment epithelium. Molecular Vision. 2012;18:519-527.
24. Takagi H, King GL, Robinson GS, et al. Adenosine mediates hypoxic induction of vascular endothelial growth factor in retinal pericytes and endothelial cells. Invest Ophthalmol Vis Sci. 1996;37(11):2165-2176.
25. Takagi H, King GL, Ferrara N, Aiello LP. Hypoxia regulates vascular endothelial growth factor receptor KDR/Flk gene expression through adenosine A2 receptors in retinal capillary endothelial cells. Invest Ophthalmol Vis Sci. 1996; 37(7):1311-1321.
26. Szaflik JP, Wysocki T. An association between vascular endothelial growth factor gene promoter polymorphisms and diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2008;246:39-43.
27. Yang Y, Andresen BT. Association of vascular endothelial growth factor-634C/G polymorphism and diabetic retinopathy in type 2 diabetic Han Chinese. Experimental Biology and Medicine. 2010;235:1204-1211.
28. Suganthalakshmi B. Association of VEGF and eNOS gene polymorphisms in type 2 diabetic retinopathy. Mol Vis. 2006;12:336-341.
29. Awata T, Inoue K. A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes. 2002; 51(5):1635-1639.
30. Zhao T, Zhao J. Association between the-634 C/G polymorphisms of the vascular endothelial growth factor and retinopathy in type 2 diabetes: A meta-analysis. Diabetes Research and Clinical Practice. 2010;90:45-53.
31. Nakamura S, Iwasaki N. Impact of variants in the VEGF gene on progression of proliferative diabetic retinopathy Graefes Arch Clin Exp Ophthalmol. 2009;247:21-26.
32. Chun MY, Hwang HS. Association of vascular endothelial growth factor polymorphisms with nonproliferative and proliferative diabetic retinopathy. J Clin Endocrinol Metab. 2010;95(7):3547-3551.
33. Nakanishi K, Watanabe C. Single nucleotide polymorphisms of vascular endothelial growth factor gene intron 2 are markers for early progression of diabetic retinopathy in Japanese with type 1 diabetes. Clinica Chimica Acta. 2009; 402:171-175.
34. Yang X, Deng Y Polymorphisms in the vascular endothelial growth factor gene and the risk of diabetic retinopathy in Chinese patients with type 2 diabetes. Molecular Vision. 2011;17:3088-3096.
35. Churchill AJ, Carter JG VEGF polymorphisms are associated with severity of diabetic retinopathy. Investigative Ophthalmology and Visual Science. 2008;49:3611-3616.
36. Liew G, Klein R. The role of genetics in susceptibility to diabetic retinopathy. Int Ophthalmol Clin. 2009;49(2):35-52.
37. Steven A. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res. 2003;63(4):812-816.
38. Ray D, Mishra M. Association of the VEGF gene with proliferative diabetic retinopathy but not proteinuria in diabetes. Diabetes 2004;53(3):861-864.
39. Ma, Y, Zhang, Y Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bavacizumab. American Journal of Ophthalmology. 2012;153: 307-313.
40. Praidou, A., Papakonstantinou, E. Vitreous and serum levels of vascular endothelial growth factor and platelet-derived growth factor and their correlation in patients with non-proliferative diabetic retinopathy and clinically significant macular oedema. Acta Ophthalmologica. 2011;89: 248-254.
41. Shimada H. Concentration gradient of vascular endothelial growth factor in the vitreous of eyes with diabetic macular edema. Investigative Ophthalmology and Visual Science. 2009; 50:2953-2955.
42. Funatsu H. Vitreous level of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology. 2006;113: 294-301.
43. Bernardi R. PML inhibits HIF-1a translation and neoan-giogenesis through repression of mTOR. Nature. 2006; 442: 779-785.
44. Katome, T. Expression of promyelocytic leukemia protein and vascular endothelial growth factor in aqueous humor and vitreous fluid in patients with proliferative diabetic retinopathy. Diabetes Research and Clinical Practice. 2012;98: e9-e11.
45. Gao BB, Clermont A. Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nature Medicine. 2007;13:181-188.
46. Gao BB, Chen X. Characterization of the vitreous proteome in diabetes without diabetic retinopathy and diabetes with proliferative diabetic retinopathy. Journal of Proteome Research. 2008;7:2516-2525.